326 related articles for article (PubMed ID: 27765906)
1. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.
Gonçalves A; Bertucci F; Guille A; Garnier S; Adelaide J; Carbuccia N; Cabaud O; Finetti P; Brunelle S; Piana G; Tomassin-Piana J; Paciencia M; Lambaudie E; Popovici C; Sabatier R; Tarpin C; Provansal M; Extra JM; Eisinger F; Sobol H; Viens P; Lopez M; Ginestier C; Charafe-Jauffret E; Chaffanet M; Birnbaum D
Oncotarget; 2016 Nov; 7(48):79428-79441. PubMed ID: 27765906
[TBL] [Abstract][Full Text] [Related]
2. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
3. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
4. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).
André F; Bachelot T; Commo F; Campone M; Arnedos M; Dieras V; Lacroix-Triki M; Lacroix L; Cohen P; Gentien D; Adélaide J; Dalenc F; Goncalves A; Levy C; Ferrero JM; Bonneterre J; Lefeuvre C; Jimenez M; Filleron T; Bonnefoi H
Lancet Oncol; 2014 Mar; 15(3):267-74. PubMed ID: 24508104
[TBL] [Abstract][Full Text] [Related]
5. Comparative genomic analysis of primary tumors and metastases in breast cancer.
Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
[TBL] [Abstract][Full Text] [Related]
6. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
[No Abstract] [Full Text] [Related]
7. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of extensive molecular profiling in advanced cancer patients.
Cousin S; Grellety T; Toulmonde M; Auzanneau C; Khalifa E; Laizet Y; Tran K; Le Moulec S; Floquet A; Garbay D; Robert J; Hostein I; Soubeyran I; Italiano A
J Hematol Oncol; 2017 Feb; 10(1):45. PubMed ID: 28179005
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of next-generation sequencing and array comparative genomic hybridization for preimplantation genetic screening: a pilot study.
Yang Z; Lin J; Zhang J; Fong WI; Li P; Zhao R; Liu X; Podevin W; Kuang Y; Liu J
BMC Med Genomics; 2015 Jun; 8():30. PubMed ID: 26100406
[TBL] [Abstract][Full Text] [Related]
10. Impact of centralization on aCGH-based genomic profiles for precision medicine in oncology.
Commo F; Ferté C; Soria JC; Friend SH; André F; Guinney J
Ann Oncol; 2015 Mar; 26(3):582-8. PubMed ID: 25538175
[TBL] [Abstract][Full Text] [Related]
11. Ready to clone: CNV detection and breakpoint fine-mapping in breast and ovarian cancer susceptibility genes by high-resolution array CGH.
Hackmann K; Kuhlee F; Betcheva-Krajcir E; Kahlert AK; Mackenroth L; Klink B; Di Donato N; Tzschach A; Kast K; Wimberger P; Schrock E; Rump A
Breast Cancer Res Treat; 2016 Oct; 159(3):585-90. PubMed ID: 27581129
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.
Kondo T; Matsubara J; Quy PN; Fukuyama K; Nomura M; Funakoshi T; Doi K; Sakamori Y; Yoshioka M; Yokoyama A; Tamaoki M; Kou T; Hirohashi K; Yamada A; Yamamoto Y; Minamiguchi S; Nishigaki M; Yamada T; Kanai M; Matsumoto S; Muto M
Cancer Sci; 2021 Jan; 112(1):296-304. PubMed ID: 33007138
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
[TBL] [Abstract][Full Text] [Related]
15. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
16. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer.
Arnedos M; Scott V; Job B; De La Cruz J; Commo F; Mathieu MC; Wolp-Diniz R; Richon C; Campone M; Bachelot T; Dalenc F; Dessen P; Lacroix L; Lazar V; Soria JC; Delaloge S; Andre F
Eur J Cancer; 2012 Oct; 48(15):2293-9. PubMed ID: 22840369
[TBL] [Abstract][Full Text] [Related]
17. What to expect from high throughput genomics in metastatic breast cancers?
Onesti CE; Vicier C; André F
Breast; 2015 Nov; 24 Suppl 2():S19-22. PubMed ID: 26238439
[TBL] [Abstract][Full Text] [Related]
18. Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
Kaur P; Porras TB; Ring A; Carpten JD; Lang JE
Sci Rep; 2019 Feb; 9(1):1482. PubMed ID: 30728399
[TBL] [Abstract][Full Text] [Related]
19. Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.
Kaderbhai CG; Boidot R; Beltjens F; Chevrier S; Arnould L; Favier L; Lagrange A; Coudert B; Ghiringhelli F
Oncotarget; 2016 Apr; 7(17):24860-70. PubMed ID: 27027238
[TBL] [Abstract][Full Text] [Related]
20. Clinical target sequencing for precision medicine of breast cancer.
Tsuchida J; Rothman J; McDonald KA; Nagahashi M; Takabe K; Wakai T
Int J Clin Oncol; 2019 Feb; 24(2):131-140. PubMed ID: 30604156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
